Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption

Publisher: John Wiley & Sons Inc

E-ISSN: 1468-3083|29|4|767-776

ISSN: 0926-9959

Source: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.29, Iss.4, 2015-04, pp. : 767-776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content